Afuco™ Anti-TNFRSF4 ADCC Therapeutic Antibody (Tavolixizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to TNFRSF4. Tavolixizumab is a humanized and chimeric monoclonal antibody that can be potentially used in the treatment of Advanced Solid Tumors.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-452CQ |
| Pricing | Inquiry |
| Host | Human |
| Target | TNFRSF4 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | ELISA, IHC, FC, IP, IF, FuncS |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |